The National Institute for Health and Care Excellence (NICE) in England is recommending natalizumab — sold as Tysabri and Tyruko — as an option for certain people with hard-to-control multiple sclerosis (MS). NICE is responsible for deciding which medicines will be covered by the National Health Service (NHS) in England, with decisions also influencing NHS […]
The post Natalizumab now recommended in England to treat hard-to-control MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com